• ROS play a critical role in tumor-associated macrophages

    ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages.Differentiation to different types of macrophages determines their distinct functions. Tumor-associated macrophages (TAMs) promote tumorigenesis owing to their proangiogenic and immune-suppressive functions similar to those of alternatively activated (M2) macrophages.

  • First-Ever CAR T-cell Therapy Approved in U.S.

    The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven not responded to standard therapy or who have relapsed at least twice.

  • CAR T cell immunotherapy in hematology and beyond

    Chimeric T cell receptors (CARs) combine extracellular antigen recognition domains and T cell activation components in single molecules. CAR gene transfer thereby allows to generate T cells with engineered specificities. The translational development of CAR-based T cell therapies is most advanced in B cell cancers where CAR-engineered T cells against the B lineage antigen CD19 have generated impressive results in early clinical trials.